The overall goal is to increase the understanding of the specific roles that the complement system plays in the immune response. Complement is centrally important in the innate immune system and linked to acquired immunity by specific receptors. In addition the complement system promotes tissue damage in inflammatory, ischemic and autoimmune diseases. Complement activation is normally regulated by intrinsic membrane proteins which form a family of complement receptors and regulatory proteins. Mouse members of this family include CR2, CR1 and Crry. Recently cDNAs or candidate proteins for additional receptors and regulatory proteins in the mouse have been identified including the platelet immune adherence receptor (IAR) and two proteins with sequence similarity to human decay-accelerating factor (DAF). To further extend the understanding of the biology activities of the RCA family, the following specific aims will be pursued:
Specific Aim 1 : Identify and characterize the specific mechanisms by which CR2 and CR1 ligation initiates, amplifies and regulates the humoral and cellular immune response.
Specific Aim 2 : Determine the impact of altered CR2 and CR1 levels and activities on autoimmune features in murine models of SLE.
Specific Aim 3 : Identify and characterize the functional activities and patterns of expression of the two murine DAF-like proteins in addition to the molecular structures and biologic roles of the immune adherence receptor (IAR).
Specific Aim 4 : Compare and contrast the effects of chronic inhibition at C3 versus C5 activation steps on normal complement physiology, susceptibility to infection, spontaneous development of immune complex deposition, and on specific phenotypic outcomes in chronic autoimmune disease models.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI031105-09
Application #
6373224
Study Section
Special Emphasis Panel (ZRG2-IMB (02))
Program Officer
Collier, Elaine S
Project Start
1993-06-01
Project End
2003-06-30
Budget Start
2001-07-01
Budget End
2002-06-30
Support Year
9
Fiscal Year
2001
Total Cost
$288,465
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Asokan, Rengasamy; Banda, Nirmal K; Szakonyi, Gerda et al. (2013) Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol 53:99-110
Elvington, Andrew; Atkinson, Carl; Kulik, Liudmila et al. (2012) Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol 188:1460-8
Thurman, Joshua M; Tchepeleva, Svetlana N; Haas, Mark et al. (2012) Complement alternative pathway activation in the autologous phase of nephrotoxic serum nephritis. Am J Physiol Renal Physiol 302:F1529-36
Renner, Brandon; Ferreira, Viviana P; Cortes, Claudio et al. (2011) Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int 80:165-73
Kulik, Liudmila; Chen, Kuan; Huber, Brigitte T et al. (2011) Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Mol Immunol 48:883-94
Renner, Brandon; Coleman, Kathrin; Goldberg, Ryan et al. (2010) The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol 185:3086-94
Renner, Brandon; Strassheim, Derek; Amura, Claudia R et al. (2010) B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J Immunol 185:4393-400
Serkova, Natalie J; Renner, Brandon; Larsen, Brian A et al. (2010) Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology 255:517-26
Kulik, Liudmila; Fleming, Sherry D; Moratz, Chantal et al. (2009) Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J Immunol 182:5363-73
Pappworth, Isabel Y; Kulik, Liudmila; Haluszczak, Catherine et al. (2009) Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21). Mol Immunol 46:1042-9

Showing the most recent 10 out of 71 publications